Evoke Pharma Inc (EVOK) 6.64 $EVOK
Evoke Pharma completes enrollment of ECG Study of EVK-001 for diabetic gastroparesis ahead of schedule
M2 - Wed Sep 10, 6:22AM CDT
Pharmaceutical company Evoke Pharma (NasdaqCM:EVOK) disclosed on Tuesday that it has completed the enrollment in its thorough ECG (electrocardiogram) (QT) study of its lead product candidate EVK-001.
Evoke Pharma Announces the Completion of Enrollment in Its Thorough ECG Study for EVK-001
GlobeNewswire - Tue Sep 09, 7:30AM CDT
Evoke Pharma, Inc. (Nasdaq:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that it has completed enrollment in its thorough ECG (QT) study of EVK-001, the Company's lead product candidate. EVK-001 is currently in a Phase 3 clinical trial for the relief of symptoms associated with acute and recurrent gastroparesis in women with diabetes mellitus.
Evoke Pharma to Present at the Aegis Capital Corp. 2014 Healthcare & Technology Conference
GlobeNewswire - Thu Sep 04, 7:35AM CDT
Evoke Pharma, Inc. (Nasdaq:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that Dave Gonyer, CEO, will present a corporate overview at the Aegis Capital Corp. 2014 Healthcare & Technology Conference, being held September 10-13, 2014 at The Encore at The Wynn in Las Vegas, Nevada. The Company is scheduled to present on Thursday, September 11, 2014 at 2:00pm PT. A copy of the corporate overview will be posted to the company's website following the presentation.
Nasdaq stocks posting largest percentage decreases
AP - Tue Aug 19, 5:09PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
Evoke Pharma Reports Second Quarter 2014 Results
GlobeNewswire - Wed Aug 13, 3:01PM CDT
Evoke Pharma, Inc. (Nasdaq:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced its financial results for the second quarter ended June 30, 2014.
Evoke Pharma Announces Initiation of a Thorough ECG (QT) Study for EVK-001
GlobeNewswire - Tue Aug 12, 4:42PM CDT
Evoke Pharma, Inc. (Nasdaq:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced the initiation of its thorough ECG (QT) study of the Company's lead product candidate, EVK-001, which is currently in a Phase 3 clinical trial for the relief of symptoms associated with acute and recurrent gastroparesis in women with diabetes mellitus.
Nasdaq stocks posting largest volume decreases
AP - Tue Aug 05, 5:06PM CDT
NEW YORK (AP) — A look at the 10 biggest volume decliners on Nasdaq at the close of trading:
Evoke Pharma Schedules Webcast and Conference Call for Second Quarter 2014 Financial Results
GlobeNewswire - Wed Jul 30, 7:40AM CDT
Evoke Pharma, Inc. (Nasdaq:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that it will issue its financial results for the second quarter of 2014 on Wednesday, August 13, 2014, after the close of the market.
Evoke Pharma Reports Fourth Quarter and Year End 2013 Results
GlobeNewswire - Tue Mar 25, 3:30PM CDT
Evoke Pharma, Inc. (Nasdaq:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced its financial results for the fourth quarter and year ended December 31, 2013.
Evoke Pharma Schedules Webcast and Conference Call for Fourth Quarter 2013 Financial Results
GlobeNewswire - Mon Mar 10, 9:02AM CDT
Evoke Pharma, Inc. (Nasdaq:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that it will issue its financial results for the Fourth Quarter of 2013 on Tuesday, March 25, 2014, after the close of the market.
Evoke Pharma to Present at 26th Annual ROTH Conference
GlobeNewswire - Tue Mar 04, 7:30AM CST
Evoke Pharma, Inc. (Nasdaq:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that its President and Chief Executive Officer, Dave Gonyer, R.Ph., will be presenting at the 26 Annual ROTH Conference, being held March 10-12, 2014 at the Ritz-Carlton in Dana Point, California.
Diabetic Gastroparesis - Pipeline Review, H1 2014 Research Report
M2 - Mon Feb 24, 3:19AM CST
Research and Markets (http://www.researchandmarkets.com/research/7ctztm/diabetic) has announced the addition of the "Diabetic Gastroparesis - Pipeline Review, H1 2014" report to their offering. 'Diabetic Gastroparesis - Pipeline Review, H1 2014', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Diabetic Gastroparesis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Diabetic Gastroparesis. Scope - A snapshot of the global therapeutic scenario for Diabetic Gastroparesis. - A review of the Diabetic Gastroparesis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Diabetic Gastroparesis pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Key Topics Covered: List of Tables List of Figures Introduction Diabetic Gastroparesis Overview Therapeutics Development Late Stage Products Clinical Stage Products Early Stage Products Unknown Stage Products Assessment by Monotherapy Products Assessment by Target Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Assessment by Therapeutic Class Drug Profiles metoclopramide hydrochloride - Drug Profile RM-131 - Drug Profile velusetrag - Drug Profile Non-Antibiotic Macrolide Program for Gastric Disorders - Drug Profile TC-6499 - Drug Profile Featured News & Press Releases Appendix List of Tables List of Figures Companies Mentioned Theravance, Inc. Evoke Pharma, Inc. Targacept, Inc. Cempra, Inc. Rhythm Pharmaceuticals For more information visit http://www.researchandmarkets.com/research/7ctztm/diabetic About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Evoke Pharma Study Reports Positive Results of Metoclopramide Nasal Spray for Gastroparesis in Diabetics
GlobeNewswire - Wed Jan 22, 7:30AM CST
Evoke Pharma, Inc. (Nasdaq:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced the publication of a study that found intranasal delivery of metoclopramide to be more effective in managing symptoms of diabetic gastroparesis compared to the marketed oral tablet formulation of metoclopramide.
Diabetic Gastroparesis Global Clinical Trials Review, H2 2013 Report Available Now
M2 - Mon Jan 13, 10:06AM CST
Research and Markets (http://www.researchandmarkets.com/research/kd5vzq/diabetic) has announced the addition of the "Diabetic Gastroparesis Global Clinical Trials Review, H2, 2013" report to their offering. The clinical trial report, Diabetic Gastroparesis Global Clinical Trials Review, H2, 2013" provides data on the Diabetic Gastroparesis clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Diabetic Gastroparesis. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Diabetic Gastroparesis. Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Companies Mentioned: - Axcan Pharma, Inc. - Duke University - Evoke Pharma, Inc. - F. Hoffmann-La Roche Ltd. - GlaxoSmithKline plc - Goteborg University - Malmo University Hospital - Novartis AG - Osaka City University - Questcor Pharmaceuticals, Inc. - Rabin Medical Center - Rhythm Pharmaceuticals - Shaare Zedek Medical Center - Targacept, Inc. - Theravance, Inc. - Tranzyme Pharma, Inc. - Vienna General Hospital - Yokohama City University For more information visit http://www.researchandmarkets.com/research/kd5vzq/diabetic About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Evoke Pharma to Present at Biotech Showcase(TM) 2014
GlobeNewswire - Tue Jan 07, 7:31AM CST
Evoke Pharma, Inc. (Nasdaq:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that its President and Chief Executive Officer, Dave Gonyer is scheduled to present at Biotech Showcase(TM) 2014, being held January 13-15, 2014 in San Francisco, Calif.
Evoke Pharma completes enrollment of ECG Study of EVK-001 for diabetic gastroparesis ahead of schedule
M2 - Wed Sep 10, 6:22AM CDT
Pharmaceutical company Evoke Pharma (NasdaqCM:EVOK) disclosed on Tuesday that it has completed the enrollment in its thorough ECG (electrocardiogram) (QT) study of its lead product candidate EVK-001.
Evoke Pharma Announces the Completion of Enrollment in Its Thorough ECG Study for EVK-001
GlobeNewswire - Tue Sep 09, 7:30AM CDT
Evoke Pharma, Inc. (Nasdaq:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that it has completed enrollment in its thorough ECG (QT) study of EVK-001, the Company's lead product candidate. EVK-001 is currently in a Phase 3 clinical trial for the relief of symptoms associated with acute and recurrent gastroparesis in women with diabetes mellitus.
Evoke Pharma to Present at the Aegis Capital Corp. 2014 Healthcare & Technology Conference
GlobeNewswire - Thu Sep 04, 7:35AM CDT
Evoke Pharma, Inc. (Nasdaq:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that Dave Gonyer, CEO, will present a corporate overview at the Aegis Capital Corp. 2014 Healthcare & Technology Conference, being held September 10-13, 2014 at The Encore at The Wynn in Las Vegas, Nevada. The Company is scheduled to present on Thursday, September 11, 2014 at 2:00pm PT. A copy of the corporate overview will be posted to the company's website following the presentation.
Nasdaq stocks posting largest percentage decreases
AP - Tue Aug 19, 5:09PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
Evoke Pharma Reports Second Quarter 2014 Results
GlobeNewswire - Wed Aug 13, 3:01PM CDT
Evoke Pharma, Inc. (Nasdaq:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced its financial results for the second quarter ended June 30, 2014.
Evoke Pharma Announces Initiation of a Thorough ECG (QT) Study for EVK-001
GlobeNewswire - Tue Aug 12, 4:42PM CDT
Evoke Pharma, Inc. (Nasdaq:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced the initiation of its thorough ECG (QT) study of the Company's lead product candidate, EVK-001, which is currently in a Phase 3 clinical trial for the relief of symptoms associated with acute and recurrent gastroparesis in women with diabetes mellitus.
Nasdaq stocks posting largest volume decreases
AP - Tue Aug 05, 5:06PM CDT
NEW YORK (AP) — A look at the 10 biggest volume decliners on Nasdaq at the close of trading:
Evoke Pharma Schedules Webcast and Conference Call for Second Quarter 2014 Financial Results
GlobeNewswire - Wed Jul 30, 7:40AM CDT
Evoke Pharma, Inc. (Nasdaq:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that it will issue its financial results for the second quarter of 2014 on Wednesday, August 13, 2014, after the close of the market.
Evoke Pharma Reports Fourth Quarter and Year End 2013 Results
GlobeNewswire - Tue Mar 25, 3:30PM CDT
Evoke Pharma, Inc. (Nasdaq:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced its financial results for the fourth quarter and year ended December 31, 2013.
Evoke Pharma Schedules Webcast and Conference Call for Fourth Quarter 2013 Financial Results
GlobeNewswire - Mon Mar 10, 9:02AM CDT
Evoke Pharma, Inc. (Nasdaq:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that it will issue its financial results for the Fourth Quarter of 2013 on Tuesday, March 25, 2014, after the close of the market.
Evoke Pharma to Present at 26th Annual ROTH Conference
GlobeNewswire - Tue Mar 04, 7:30AM CST
Evoke Pharma, Inc. (Nasdaq:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that its President and Chief Executive Officer, Dave Gonyer, R.Ph., will be presenting at the 26 Annual ROTH Conference, being held March 10-12, 2014 at the Ritz-Carlton in Dana Point, California.
Diabetic Gastroparesis - Pipeline Review, H1 2014 Research Report
M2 - Mon Feb 24, 3:19AM CST
Research and Markets (http://www.researchandmarkets.com/research/7ctztm/diabetic) has announced the addition of the "Diabetic Gastroparesis - Pipeline Review, H1 2014" report to their offering. 'Diabetic Gastroparesis - Pipeline Review, H1 2014', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Diabetic Gastroparesis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Diabetic Gastroparesis. Scope - A snapshot of the global therapeutic scenario for Diabetic Gastroparesis. - A review of the Diabetic Gastroparesis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Diabetic Gastroparesis pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Key Topics Covered: List of Tables List of Figures Introduction Diabetic Gastroparesis Overview Therapeutics Development Late Stage Products Clinical Stage Products Early Stage Products Unknown Stage Products Assessment by Monotherapy Products Assessment by Target Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Assessment by Therapeutic Class Drug Profiles metoclopramide hydrochloride - Drug Profile RM-131 - Drug Profile velusetrag - Drug Profile Non-Antibiotic Macrolide Program for Gastric Disorders - Drug Profile TC-6499 - Drug Profile Featured News & Press Releases Appendix List of Tables List of Figures Companies Mentioned Theravance, Inc. Evoke Pharma, Inc. Targacept, Inc. Cempra, Inc. Rhythm Pharmaceuticals For more information visit http://www.researchandmarkets.com/research/7ctztm/diabetic About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Evoke Pharma Study Reports Positive Results of Metoclopramide Nasal Spray for Gastroparesis in Diabetics
GlobeNewswire - Wed Jan 22, 7:30AM CST
Evoke Pharma, Inc. (Nasdaq:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced the publication of a study that found intranasal delivery of metoclopramide to be more effective in managing symptoms of diabetic gastroparesis compared to the marketed oral tablet formulation of metoclopramide.
Diabetic Gastroparesis Global Clinical Trials Review, H2 2013 Report Available Now
M2 - Mon Jan 13, 10:06AM CST
Research and Markets (http://www.researchandmarkets.com/research/kd5vzq/diabetic) has announced the addition of the "Diabetic Gastroparesis Global Clinical Trials Review, H2, 2013" report to their offering. The clinical trial report, Diabetic Gastroparesis Global Clinical Trials Review, H2, 2013" provides data on the Diabetic Gastroparesis clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Diabetic Gastroparesis. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Diabetic Gastroparesis. Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Companies Mentioned: - Axcan Pharma, Inc. - Duke University - Evoke Pharma, Inc. - F. Hoffmann-La Roche Ltd. - GlaxoSmithKline plc - Goteborg University - Malmo University Hospital - Novartis AG - Osaka City University - Questcor Pharmaceuticals, Inc. - Rabin Medical Center - Rhythm Pharmaceuticals - Shaare Zedek Medical Center - Targacept, Inc. - Theravance, Inc. - Tranzyme Pharma, Inc. - Vienna General Hospital - Yokohama City University For more information visit http://www.researchandmarkets.com/research/kd5vzq/diabetic About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Evoke Pharma to Present at Biotech Showcase(TM) 2014
GlobeNewswire - Tue Jan 07, 7:31AM CST
Evoke Pharma, Inc. (Nasdaq:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that its President and Chief Executive Officer, Dave Gonyer is scheduled to present at Biotech Showcase(TM) 2014, being held January 13-15, 2014 in San Francisco, Calif.
